drugset / Trial / NCT04212013
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Phase 3
Active not recruiting
23 enrolled
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.
Timeline
- Start
- 2019-12-23
- Primary completion
- 2027-03-18
- Completion
- 2027-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 560 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |